PopPK

Envafolimab subcutaneous population PK

A subcutaneous population PK model representing envafolimab absorption, systemic concentration, renal-function covariates, and time-varying clearance.

Explore and simulate

Therapeutic: Envafolimab
Target: PD-L1 / CD274
Disease: PD-L1-positive solid tumors

Biological model

A subcutaneous population PK model representing envafolimab absorption, systemic concentration, renal-function covariates, and time-varying clearance.

Intervention

Envafolimab

Biological focus

PD-L1 / CD274

Context

PD-L1-positive solid tumors

Model details

A subcutaneous population PK model representing envafolimab absorption, systemic concentration, renal-function covariates, and time-varying clearance.

Modeled states

auc mg day lmg*day/L

Modeled dynamic state for auc mg day l.
central mgmg

Modeled dynamic state for central mg.
depot mgmg

Modeled dynamic state for depot mg.
elapsed dayday

Modeled dynamic state for elapsed day.

Key readouts

Envafolimab concentrationunknown

Model-derived readout for envafolimab concentration.
Cumulative envafolimab exposuremg*day/L

Model-derived readout for cumulative envafolimab exposure.
Individual clearanceunknown

Model-derived readout for individual clearance.
Absorption rateunknown

Model-derived readout for absorption rate.
auc mg h lunknown

Model-derived readout for auc mg h l.

Explore this model

Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.

Starting configuration

Final model 150 mg QW for 20 weeks

How do dosing interval, renal function, and time-varying clearance change envafolimab exposure? Explore this intervention regimen through Envafolimab concentration, Cumulative envafolimab exposure, Individual clearance, Absorption rate. This is a mechanistic product exploration, not a paper-result reproduction.

Questions to explore

How do dosing interval, renal function, and time-varying clearance change envafolimab exposure?

Starting result

This result reflects the starting settings. Run your changes to update it.

This scenario result is temporarily unavailable.

Model inputs

Five scientist-facing controls at most.

ka hr Model parameter controlling ka hr. 1/hrtheta cl l hr Model parameter controlling theta cl l hr. L/hrv l Model parameter controlling v l. Lt50 day Model parameter controlling t50 day. daycrcl ml min Model parameter controlling crcl ml min. mL/min

Compare a parameter

How does one model input change the response?

How do dosing interval, renal function, and time-varying clearance change envafolimab exposure?

Parameter to compare

ka hr

Model parameter controlling ka hr.

Exploratory range around the default value.

Low High Points

5 evenly spaced values in 1/hr. Other model inputs and the simulation window stay fixed.

Interpret with care

Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.
Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario.

Review the server-confirmed fixed price before starting the comparison.

Comparative response

End-of-window response across the selected parameter values.

Choose an exploratory range around the default, review the fixed price, and run the comparison.

Scientific reference

Supporting publication

Model-informed drug development of envafolimab, a subcutaneously injectable PD-L1 antibody, in patients with advanced solid tumors

The Oncologist